Bristol-Myers Squibb Co had a surprising announcement on Thursday as it reported financial results. The pharma giant revealed to Wall Street that it has withdrew its application for U.S. approval for a combination of its blockbuster cancer immunotherapy drugs Opdivo and Yervoy as an initial treatment for advanced lung cancer. The company will be working … Continue reading “Bristol-Myers Has Withdrew its Application for Combination Lung Cancer Treatment”
Tag: opdivo
Biotech & Pharma
Bristol-Myers Squibb Gets FDA Approval for its Liver Drug Opdivo
It was an exciting day for Bristol-Myers Squibb on Monday. The Food and Drug Administration…
September 25, 2017